Matches in SemOpenAlex for { <https://semopenalex.org/work/W960967595> ?p ?o ?g. }
- W960967595 endingPage "275" @default.
- W960967595 startingPage "263" @default.
- W960967595 abstract "Histone deacetylases (HDAC) which play a crucial role in cancer cell proliferation are promising drug targets. However, HDAC inhibitors (HDACi) modelled on natural hydroxamic acids such as trichostatin A frequently lead to resistance or even an increased agressiveness of tumours. As a workaround we developed 4-(1-ethyl-4-anisyl-imidazol-5-yl)-N-hydroxycinnamide (etacrox), a hydroxamic acid that combines HDAC inhibition with synergistic effects of the 4,5-diarylimidazole residue. Etacrox proved highly cytotoxic against a panel of metastatic and resistant cancer cell lines while showing greater specificity for cancer over non-malignant cells when compared to the approved HDACi vorinostat. Like the latter, etacrox and the closely related imidazoles bimacroxam and animacroxam acted as pan-HDACi yet showed some specificity for HDAC6. Akt signalling and interference with nuclear beta-catenin localisation were elicited by etacrox at lower concentrations when compared to vorinostat. Moreover, etacrox disrupted the microtubule and focal adhesion dynamics of cancer cells and inhibited the proteolytic activity of prometastatic and proangiogenic matrix metalloproteinases. As a consequence, etacrox acted strongly antimigratory and antiinvasive against various cancer cell lines in three-dimensional transwell invasion assays and also antiangiogenic in vivo with respect to blood vessel formation in the chorioallantoic membrane assay. These pleiotropic effects and its water-solubility and tolerance by mice render etacrox a promising new HDACi candidate." @default.
- W960967595 created "2016-06-24" @default.
- W960967595 creator A5010269033 @default.
- W960967595 creator A5026002243 @default.
- W960967595 creator A5060783643 @default.
- W960967595 creator A5085134262 @default.
- W960967595 date "2015-08-01" @default.
- W960967595 modified "2023-09-25" @default.
- W960967595 title "4-(1-Ethyl-4-anisyl-imidazol-5-yl)-N-hydroxycinnamide – A new pleiotropic HDAC inhibitor targeting cancer cell signalling and cytoskeletal organisation" @default.
- W960967595 cites W1486094676 @default.
- W960967595 cites W1561407320 @default.
- W960967595 cites W196082105 @default.
- W960967595 cites W1967009719 @default.
- W960967595 cites W1968972540 @default.
- W960967595 cites W1972005136 @default.
- W960967595 cites W1972149587 @default.
- W960967595 cites W1974911471 @default.
- W960967595 cites W1989763558 @default.
- W960967595 cites W1993243592 @default.
- W960967595 cites W1998499089 @default.
- W960967595 cites W2011074386 @default.
- W960967595 cites W2012586673 @default.
- W960967595 cites W2014364284 @default.
- W960967595 cites W2015047229 @default.
- W960967595 cites W2015082085 @default.
- W960967595 cites W2017410521 @default.
- W960967595 cites W2024013245 @default.
- W960967595 cites W2029130907 @default.
- W960967595 cites W2031462792 @default.
- W960967595 cites W2031671750 @default.
- W960967595 cites W2037548392 @default.
- W960967595 cites W2045251122 @default.
- W960967595 cites W2046746554 @default.
- W960967595 cites W2051709854 @default.
- W960967595 cites W2052368458 @default.
- W960967595 cites W2052453190 @default.
- W960967595 cites W2053344100 @default.
- W960967595 cites W2061396130 @default.
- W960967595 cites W2061698887 @default.
- W960967595 cites W2063078660 @default.
- W960967595 cites W2063473163 @default.
- W960967595 cites W2064959533 @default.
- W960967595 cites W2066264051 @default.
- W960967595 cites W2071559249 @default.
- W960967595 cites W2073189570 @default.
- W960967595 cites W2073978750 @default.
- W960967595 cites W2074995471 @default.
- W960967595 cites W2076583198 @default.
- W960967595 cites W2081421175 @default.
- W960967595 cites W2083535354 @default.
- W960967595 cites W2086384126 @default.
- W960967595 cites W2086641174 @default.
- W960967595 cites W2088233020 @default.
- W960967595 cites W2088418811 @default.
- W960967595 cites W2093419517 @default.
- W960967595 cites W2099803844 @default.
- W960967595 cites W2100794280 @default.
- W960967595 cites W2101179492 @default.
- W960967595 cites W2102921200 @default.
- W960967595 cites W2103665811 @default.
- W960967595 cites W2104535331 @default.
- W960967595 cites W2114072364 @default.
- W960967595 cites W2117228071 @default.
- W960967595 cites W2117298794 @default.
- W960967595 cites W2131485957 @default.
- W960967595 cites W2135830745 @default.
- W960967595 cites W2138879453 @default.
- W960967595 cites W2148495272 @default.
- W960967595 cites W2149386327 @default.
- W960967595 cites W2149555430 @default.
- W960967595 cites W2156363416 @default.
- W960967595 cites W2156560911 @default.
- W960967595 cites W2158087280 @default.
- W960967595 cites W2159648717 @default.
- W960967595 cites W2324889213 @default.
- W960967595 cites W4210961478 @default.
- W960967595 doi "https://doi.org/10.1016/j.yexcr.2015.06.008" @default.
- W960967595 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26101158" @default.
- W960967595 hasPublicationYear "2015" @default.
- W960967595 type Work @default.
- W960967595 sameAs 960967595 @default.
- W960967595 citedByCount "8" @default.
- W960967595 countsByYear W9609675952016 @default.
- W960967595 countsByYear W9609675952017 @default.
- W960967595 countsByYear W9609675952018 @default.
- W960967595 countsByYear W9609675952019 @default.
- W960967595 countsByYear W9609675952020 @default.
- W960967595 countsByYear W9609675952021 @default.
- W960967595 crossrefType "journal-article" @default.
- W960967595 hasAuthorship W960967595A5010269033 @default.
- W960967595 hasAuthorship W960967595A5026002243 @default.
- W960967595 hasAuthorship W960967595A5060783643 @default.
- W960967595 hasAuthorship W960967595A5085134262 @default.
- W960967595 hasConcept C104317684 @default.
- W960967595 hasConcept C121608353 @default.
- W960967595 hasConcept C2776262904 @default.
- W960967595 hasConcept C2778305200 @default.
- W960967595 hasConcept C502942594 @default.